GLP-1 Medications and Cancer Risk Reduction: Colorectal, Liver, and Endometrial

Research examining GLP-1 medications cancer risk is accelerating, with 2025 and 2026 studies showing associations between semaglutide and tirzepatide use and lower rates of colorectal, liver, and endometrial malignancies in people with obesity and type 2 diabetes.

*Compounded semaglutide and compounded tirzepatide are not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Clinical data referenced here reflects studies of FDA-approved pharmaceutical compounds unless otherwise noted. Compounded medications have not been studied in the cancer-risk trials described below, and no cancer prevention claims are made for compounded GLP-1 products. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication. Care at Prescriva is delivered by independently licensed providers, not by Blue Oak Services LLC dba Prescriva, which is a management services organization.*

---

Obesity increases the risk of at least 13 different cancers. For years, that fact lived mostly in oncology textbooks. Now, as millions of people use GLP-1 receptor agonists for weight management, researchers are asking a pointed question: what happens to cancer incidence when those same people lose substantial amounts of weight and reduce systemic inflammation through GLP-1 therapy?

The early answers are appearing in high-impact journals, and they are consistently pointing in one direction. This article looks specifically at three obesity-associated cancer types where the evidence is accumulating most rapidly: colorectal cancer, liver cancer (hepatocellular carcinoma), and endometrial cancer.

This is not a claim that GLP-1 medications prevent or treat cancer. That is not established. What is established is a pattern of findings suggesting that GLP-1 receptor agonist use is associated with reduced incidence of these cancers in high-risk populations, and the biology connecting obesity, metabolic dysfunction, and cancer helps explain why.

---

Why These Three Cancers

Colorectal, liver, and endometrial cancer share a common upstream contributor: obesity-driven metabolic dysregulation.

A foundational 2019 review in *Metabolism: Clinical and Experimental* identified the three core mechanisms through which obesity promotes cancer development (PMID 30445141, Avgerinos et al.):

Chronic systemic inflammation. Excess adipose tissue releases pro-inflammatory cytokines including TNF-alpha and interleukin-6 at persistently elevated levels. This environment suppresses immune surveillance and favors the survival and proliferation of malignant cells.

Hyperinsulinemia and IGF-1 signaling. Obesity drives insulin resistance, which forces compensatory overproduction of insulin. Elevated insulin and insulin-like growth factor 1 (IGF-1) act as growth signals on cancer cells that express insulin receptors.

Adipokine imbalance. In people with obesity, leptin levels rise and adiponectin levels fall. Leptin promotes cell proliferation; adiponectin inhibits it. The shift in this balance creates a hormonal environment that favors tumor growth.

All three mechanisms operate directly in colorectal, liver, and endometrial tissue. GLP-1 receptor agonists, through weight reduction and their independent anti-inflammatory effects, act on all three pathways.

---

Colorectal Cancer: The Most Studied Association

Colorectal cancer sits at the intersection of metabolic disease and cancer research. The colon is directly exposed to the metabolic outputs of diet and fat distribution, and insulin resistance is a well-established colorectal cancer risk factor.

A 2026 systematic review and network meta-analysis published in *Diabetes/Metabolism Research and Reviews* examined GLP-1 receptor agonist use and colon cancer risk in adults with type 2 diabetes or obesity (PMID 41668634, Guo M et al.). The analysis found that GLP-1 receptor agonist use was associated with a statistically significant reduction in colon cancer risk compared to other glucose-lowering therapies and placebo. The authors attributed this to the combined effect of weight reduction, improved metabolic control, and the anti-inflammatory properties of GLP-1 receptor agonism.

A companion 2026 meta-analysis published in *Frontiers in Pharmacology* extended this analysis to the full category of gastrointestinal malignancies, including both colorectal and gastric cancers (PMID 41743116, Wali AF et al.). The authors concluded that GLP-1 receptor agonist use was associated with reduced risk across gastrointestinal cancers in populations with obesity and type 2 diabetes, and described the drug class as demonstrating a "more favorable cancer risk profile than previously appreciated."

A broader 2026 systematic review in *Diabetes Research and Clinical Practice* synthesized data across all obesity-related cancers, including colorectal, and found consistent signals of risk reduction with GLP-1 receptor agonist use (PMID 41722869, Ateiwi YA et al.).

These are large-scale observational and meta-analytic findings, not randomized prevention trials. They cannot establish that GLP-1 medications caused the lower cancer rates. But the consistency of the signal across multiple independent research groups adds weight to the biological plausibility of the association.

<img src="/images/articles/glp1-medications-inflammation-crp-research-hero.jpg" alt="Scientific research visualization showing inflammation biomarkers, warm amber tones, Prescriva health education style" />

---

Liver Cancer: New and Rapidly Evolving Evidence

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. It is closely tied to metabolic liver disease, including metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and liver cirrhosis, both of which are strongly associated with obesity and type 2 diabetes.

A July 2026 population-based cohort study published in *Diabetes, Obesity and Metabolism* examined the association between semaglutide treatment and the development of liver cirrhosis and hepatocellular carcinoma in people with type 2 diabetes (PMID 41969200, Issachar A et al.). The study found that semaglutide use was associated with significantly lower rates of both liver cirrhosis progression and hepatocellular carcinoma compared to matched controls not receiving semaglutide.

A complementary 2025 scoping review in *Cureus* evaluated the full body of evidence on GLP-1 receptor agonists and HCC risk and management (PMID 41607999, Tungekar B et al.). The authors identified consistent signals of hepatoprotective effects across the GLP-1 class, driven by reductions in hepatic steatosis, liver inflammation, and fibrosis, each of which is a step in the progression from metabolic liver disease to cirrhosis to HCC.

A July 2026 target trial emulation study published in *Gut* went one step further and examined outcomes in people who had already had liver resection surgery for HCC and had type 2 diabetes (PMID 42399086, Xiang YJ et al.). The study compared GLP-1 receptor agonist use to DPP-4 inhibitor use after HCC surgery and found that the GLP-1 receptor agonist group had meaningfully better recurrence-related outcomes. This suggests a possible role for GLP-1 therapy not only in primary prevention but also in the management of HCC in people with comorbid type 2 diabetes, though this remains an area of active investigation and is not a current standard of care.

The mechanism connecting GLP-1 medications to lower HCC risk runs through the liver itself. GLP-1 receptors are expressed in hepatocytes, and GLP-1 receptor agonism reduces hepatic fat accumulation, lowers liver enzyme levels, reduces fibrosis, and decreases hepatic inflammation. In people with metabolic liver disease, these effects may slow or interrupt the pathway that leads to HCC over years or decades.

---

Endometrial Cancer: A Meaningful Signal in Women With Obesity

Endometrial cancer (cancer of the uterine lining) is the most common gynecologic malignancy in the United States. It is one of the cancers most directly linked to obesity, because adipose tissue in people with obesity produces estrogen independently of the ovaries through a process called aromatization. Excess estrogen stimulates the growth of the endometrial lining and is a primary driver of endometrial cancer development, particularly in postmenopausal women and women with polycystic ovary syndrome (PCOS).

A February 2026 study published in *JAMA Network Open* examined whether GLP-1 receptor agonist use was associated with reduced endometrial cancer risk in women with nonmalignant uterine diseases (PMID 41665904, Yen TT et al.). The study examined women using GLP-1 receptor agonists with or without progestin therapy and found that GLP-1 receptor agonist use was associated with a lower risk of endometrial cancer development compared to non-users, with the association strengthened in combination with progestin.

The mechanism here is less about direct GLP-1 receptor effects on endometrial tissue and more about downstream metabolic effects. Weight loss reduces the production of estrogen from adipose tissue, restores menstrual regularity in women with PCOS and anovulation, and improves insulin sensitivity, which itself is a driver of endometrial proliferation through insulin receptor signaling on endometrial cells.

A 2026 *J Gen Intern Med* analysis of cancer incidence across a large GLP-1 user population confirmed that endometrial cancer was among the malignancies showing lower incidence in GLP-1 receptor agonist users compared to control groups (PMID 41749007, Rashid Z et al.).

For women with obesity and elevated endometrial cancer risk factors (PCOS, prolonged anovulation, postmenopausal status with obesity), these findings add a dimension to the discussion of GLP-1 therapy beyond weight management.

---

Important Context: What This Evidence Can and Cannot Tell Us

The research reviewed here is consistent and grounded in well-established biology. However, several limitations are important for any honest evaluation of these findings.

Observational design. The studies described are largely retrospective cohort studies, population-based analyses, and meta-analyses of observational data. Observational studies cannot prove causality. People prescribed GLP-1 medications may differ in ways that affect their cancer risk beyond the medication itself.

Population specifics. Most studies were conducted in populations with type 2 diabetes or clinically significant obesity. The degree to which findings apply to people using GLP-1 medications primarily for modest weight loss without these comorbidities is not established.

Compounded products are not studied. All cancer-related research on GLP-1 medications involves FDA-approved branded pharmaceutical compounds. Compounded semaglutide and tirzepatide have not been studied for cancer risk outcomes and carry no cancer prevention claim or implication.

No randomized cancer prevention trials exist. The gold standard for establishing that a drug reduces cancer risk is a large, long-term, randomized controlled trial with cancer incidence as the primary endpoint. Those trials have not been conducted for GLP-1 medications. The SELECT cardiovascular outcomes trial (semaglutide vs. placebo in people with obesity and established cardiovascular disease) included cancer as a prespecified secondary endpoint; those results and longer-term follow-up will add important data.

What the current evidence does establish: in populations with obesity and metabolic disease, GLP-1 receptor agonist use is consistently associated with lower rates of colorectal, liver, and endometrial cancers in ways that align with known biology. That is a meaningful scientific finding, even if it is not yet a clinical practice guideline.

---

What to Discuss With Your Healthcare Provider

If you are managing obesity and have personal or family history of colorectal, liver, or endometrial cancer, the cancer risk data on GLP-1 medications adds relevant context to a conversation you should be having with your provider anyway about comprehensive obesity management.

GLP-1 medications prescribed for obesity at Prescriva are evaluated by licensed healthcare providers based on your individual health history, not population averages. The cancer risk data does not change the indications for these medications, and GLP-1 medications should not be pursued for cancer risk reduction as a primary goal.

What it does reinforce: weight management is not a cosmetic goal. Managing obesity through evidence-based treatment addresses multiple organ systems simultaneously, including metabolic pathways that influence long-term cancer risk.

---

The Takeaway

Three of the cancers most closely linked to obesity (colorectal, liver, and endometrial) are showing consistent signals of lower incidence in populations using GLP-1 receptor agonists. A 2026 network meta-analysis (PMID 41668634) confirmed reduced colorectal cancer risk. A 2026 population-based cohort study (PMID 41969200) found lower hepatocellular carcinoma rates with semaglutide. A 2026 *JAMA Network Open* study (PMID 41665904) found lower endometrial cancer risk in GLP-1 receptor agonist users.

The mechanisms are grounded in known biology: weight reduction, reduced systemic inflammation, improved insulin sensitivity, and lower estrogen production from adipose tissue all move in directions that reduce cancer risk. These findings are observational, not confirmatory, and apply to FDA-approved branded GLP-1 medications in studied populations.

If you would like to speak with a licensed provider about whether a medically supervised GLP-1 program is appropriate for your health circumstances, Prescriva connects you with independently licensed clinicians who can evaluate your individual situation.

*This article is for educational purposes only and does not constitute medical advice. Consult your licensed healthcare provider before making any treatment decisions.*

---

Explore related articles:

• [GLP-1 Medications and Cancer Risk Research](/resources/glp1-medications-cancer-risk-research)
• [GLP-1 Medications and Inflammation Research](/resources/glp1-medications-inflammation-research)
• [GLP-1 Medications and Fatty Liver Disease](/resources/glp1-medications-fatty-liver)
• [Semaglutide and Thyroid Cancer Risk](/resources/semaglutide-thyroid-cancer-risk)

References:

1. Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. *Metabolism.* 2019;93:121-135. PMID: 30445141

1. Guo M, et al. Association Between GLP-1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta-Analysis. *Diabetes/Metabolism Research and Reviews.* 2026 Feb. PMID: 41668634

1. Wali AF, et al. Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies. *Frontiers in Pharmacology.* 2026. PMID: 41743116

1. Ateiwi YA, et al. Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis. *Diabetes Research and Clinical Practice.* 2026 Apr. PMID: 41722869

1. Issachar A, et al. Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population-Based Cohort Study. *Diabetes, Obesity and Metabolism.* 2026 Jul. PMID: 41969200

1. Xiang YJ, et al. Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study. *Gut.* 2026 Jul. PMID: 42399086

1. Tungekar B, et al. Impact of Glucagon-Like Peptide-1 Agonists on Hepatocellular Carcinoma Risk and Management in Type 2 Diabetes Mellitus: A Scoping Review. *Cureus.* 2025 Dec. PMID: 41607999

1. Yen TT, et al. GLP-1 Receptor Agonists Plus Progestins and Endometrial Cancer Risk in Nonmalignant Uterine Diseases. *JAMA Network Open.* 2026 Feb 2. PMID: 41665904

1. Rashid Z, et al. Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists. *Journal of General Internal Medicine.* 2026 May. PMID: 41749007